文献速递心力衰竭与心肌病

老年心力衰竭:流行病学、机制与管理

Heart failure in the elderly: epidemiology, mechanisms, and management.
PubMed 文献 · Eur Heart J · 2026-01-01

本文综述老年心力衰竭的流行病学、生物学机制及治疗管理。心力衰竭终生风险约25%,70岁后发病率急剧上升。指南指导的药物治疗仍是各年龄段基石,但高龄特征常限制足量应用,器械治疗需权衡非心脏竞争风险。

要点

  • 心力衰竭终生风险约25%,70岁后发病率急剧增加。
  • 老年患者常因低血压和衰弱无法耐受足量指南指导的药物治疗。
  • 应及时与老年心衰患者讨论预立医疗计划和临终决策。

核心结论

  • 指南指导的药物治疗仍是各年龄段心衰治疗的基石,包括能耐受的老年患者。
  • 高龄相关机制目前未被指南推荐的药物治疗所覆盖。

研究设计与样本

  • 本文为综述,未报告具体检索范围。

主要发现

  • 心力衰竭终生风险约25%,70岁后发病率急剧增加。
  • 男性和女性终生风险几乎相等,女性更倾向于射血分数保留的心衰,男性更倾向于射血分数降低的心衰。
  • 生物衰老过程中自噬和蛋白质稳态受损、线粒体功能障碍、氧化应激、细胞衰老、意义未明的克隆性造血和慢性低度炎症共同损害心肌。
  • 高龄患者合并症负担重,低血压和衰弱常阻碍足量指南指导的药物治疗。

关键数值与推荐

  • 对老年心衰的年龄界定尚无共识。
  • 多数心衰患者为高龄人群。
  • 器械治疗的风险获益比需结合该人群普遍存在的非心脏竞争风险审慎评估。

临床怎么用

  • 对能耐受的老年心衰患者仍应使用指南指导的药物治疗。
  • 老年患者启动器械治疗前需审慎权衡非心脏竞争风险。
  • 应在适当时机与老年心衰患者讨论预立医疗计划和临终决策。

局限性

  • 未提供具体检索策略和纳入排除标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is no consensus on an age cut-off for being considered elderly, but the majority of patients with heart failure (HF) have an advanced age. The lifetime risk for developing HF is ∼25%, with a sharp increase in incidence after the age of 70. The lifetime risk for men and women is almost equal, but women exhibit a higher propensity towards developing HF with preserved ejection fraction, whereas men are more prone to HF with reduced ejection fraction. During the biological ageing process, several systemic and local pathophysiological alterations impact the myocardium, including impaired autophagy and proteostasis, mitochondrial dysfunction, and oxidative stress, as well as cellular senescence, clonal haematopoiesis of indeterminate potential, and chronic low-grade inflammation or inflammaging. Collectively, these changes compromise cardiac energy homeostasis and promote cell loss and dysfunction, increasing the risk of HF. Despite their relevance, these ageing-related mechanisms are hitherto not addressed by guideline-recommended medical therapy. Guideline-recommended medical therapy remains the cornerstone of HF treatment across age groups, including in elderly patients who tolerate it. However, a high burden of comorbidities and several features specific to advanced age, such as low blood pressure and frailty, often preclude full-dose guideline-recommended medical therapy. Similarly, the risk-benefit ratio of device therapies needs careful consideration in light of competing non-cardiac risks due to comorbidities that are prevalent in this population. Finally, HF is a mortal condition, and advanced care planning and end-of-life decisions should be discussed in a timely manner in elderly patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. de Boer, Abdellatif, Bauersachs, et al. Heart failure in the elderly: epidemiology, mechanisms, and management. Eur Heart J. 2026. PMID: 41760079. doi:10.1093/eurheartj/ehag110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。